Cargando…
Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
BACKGROUND: Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy. ICI therapy is generally better tolerated than cytotoxic chemotherapy; however, hematological adverse events (AEs) have not been fully analyzed. Hence, we performed a meta-analysis to evaluate the incidence a...
Autores principales: | Ohashi, Takuma, Takase-Minegishi, Kaoru, Maeda, Ayaka, Hamada, Naoki, Yoshimi, Ryusuke, Kirino, Yohei, Teranaka, Hiroshi, Kunimoto, Hiroyoshi, Hagihara, Maki, Matsumoto, Kenji, Namkoong, Ho, Horita, Nobuyuki, Nakajima, Hideaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181326/ https://www.ncbi.nlm.nih.gov/pubmed/37187501 http://dx.doi.org/10.14740/jh1090 |
Ejemplares similares
-
Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
por: Hamada, Naoki, et al.
Publicado: (2021) -
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience
por: Adachi, Soichiro, et al.
Publicado: (2023) -
Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan
por: Kunishita, Yosuke, et al.
Publicado: (2022) -
The Roles of Monocytes and Macrophages in Behçet’s Disease With Focus on M1 and M2 Polarization
por: Hirahara, Lisa, et al.
Publicado: (2022) -
The PRY/SPRY domain of pyrin/TRIM20 interacts with β(2)-microglobulin to promote inflammasome formation
por: Samukawa, Sei, et al.
Publicado: (2021)